Robert Nelsen, a partner at ARCH Venture Partners, has strategically invested in pioneering companies at the cutting edge of oncology research and innovation. Through his involvement with Boundless Bio, Myeloid Therapeutics, OncoResponse, and Carrick Therapeutics, Nelsen demonstrates his unwavering commitment to advancing breakthrough therapies and technologies in the field of oncology.